| scholarly article | Q13442814 |
| P2093 | author name string | Bouma BN | |
| Meijers JC | |||
| Levi M | |||
| ten Cate H | |||
| Hack CE | |||
| Minnema MC | |||
| Biemond BJ | |||
| Friederich PW | |||
| Mosnier LO | |||
| von dem Borne PA | |||
| P2860 | cites work | Plasma carboxypeptidases as regulators of the plasminogen system | Q24677226 |
| TAFI, or plasma procarboxypeptidase B, couples the coagulation and fibrinolytic cascades through the thrombin-thrombomodulin complex | Q28281969 | ||
| Clot-bound thrombin is protected from inhibition by heparin-antithrombin III but is susceptible to inactivation by antithrombin III-independent inhibitors | Q28294390 | ||
| Activation and characterization of procarboxypeptidase B from human plasma | Q28300347 | ||
| Tissue factor and hemostasis | Q28630773 | ||
| The tissue factor pathway: how it has become a "prima ballerina" | Q28631248 | ||
| Purification and characterization of TAFI, a thrombin-activable fibrinolysis inhibitor | Q34059019 | ||
| Factor XI deficiency in Ashkenazi Jews in Israel | Q34118794 | ||
| The coagulation-kinin pathway of human plasma | Q34687103 | ||
| Thrombin-mediated activation of factor XI results in a thrombin-activatable fibrinolysis inhibitor-dependent inhibition of fibrinolysis | Q39784189 | ||
| An intrinsic factor XII- prekallikrein-dependent pathway activates the human plasma renin-angiotensin system | Q41700499 | ||
| Naturally occurring human antibodies against two distinct functional domains in the heavy chain of FXI/FXIa. | Q46398550 | ||
| Evidence suggestive of activation of the intrinsic pathway of blood coagulation after injection of factor Xa/phospholipid into rabbits | Q46707845 | ||
| Factor XIa induced activation of the intrinsic cascade in vivo. | Q52845859 | ||
| Rabbit blood coagulation factor XI. Purification and properties | Q57741003 | ||
| Dental surgery in patients with severe factor XI deficiency without plasma replacement | Q67918855 | ||
| Comparison of bleeding tendency, factor XI coagulant activity, and factor XI antigen in 25 factor XI-deficient kindreds | Q69865005 | ||
| Comparison of sustained antithrombotic effects of inhibitors of thrombin and factor Xa in experimental thrombosis | Q71046994 | ||
| Effect of heparin on the activation of factor XI by fibrin-bound thrombin | Q71709876 | ||
| Feedback activation of factor XI by thrombin in plasma results in additional formation of thrombin that protects fibrin clots from fibrinolysis | Q71789536 | ||
| Factor XI deficiency | Q72595231 | ||
| The influence of fibrinogen and fibrin on thrombin generation--evidence for feedback activation of the clotting system by clot bound thrombin | Q72653551 | ||
| On the mechanism of the antifibrinolytic activity of plasma carboxypeptidase B | Q73363110 | ||
| The partial thromboplastin time with kaolin. A simple screening test for first stage plasma clotting factor deficiencies | Q78981048 | ||
| P433 | issue | 1 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | thrombolysis | Q1931577 |
| P304 | page(s) | 10-14 | |
| P577 | publication date | 1998-01-01 | |
| P1433 | published in | Journal of Clinical Investigation | Q3186904 |
| P1476 | title | Enhancement of rabbit jugular vein thrombolysis by neutralization of factor XI. In vivo evidence for a role of factor XI as an anti-fibrinolytic factor | |
| P478 | volume | 101 |
| Q35081838 | Activated protein C resistance (FV(Leiden)) and thrombosis: factor V mutations causing hypercoagulable states |
| Q40603732 | Activation of coagulation factor XI, without detectable contact activation in dengue haemorrhagic fever. |
| Q28564560 | Adjuvant effect of antibodies against von Willebrand Factor, fibrinogen, and fibronectin on staphylokinase-induced thrombolysis as measured using mural thrombi formed in rat mesenteric venules |
| Q33902731 | An inhibitor of activated thrombin-activatable fibrinolysis inhibitor potentiates tissue-type plasminogen activator-induced thrombolysis in a rabbit jugular vein thrombolysis model |
| Q37739907 | Antithrombotic therapy in acute coronary syndrome: how far up the coagulation cascade will we go? |
| Q34376924 | Basic principles in thrombolysis: regulatory role of plasminogen |
| Q37095385 | Beta 2-Glycoprotein I binds factor XI and inhibits its activation by thrombin and factor XIIa: loss of inhibition by clipped beta 2-glycoprotein I. |
| Q35574076 | Can the time window for administration of thrombolytics in stroke be increased? |
| Q44314786 | Carboxypeptidase B inhibitors reduce tissue factor-induced renal microthrombi in rats |
| Q35208114 | Carboxypeptidase U (TAFIa): a new drug target for fibrinolytic therapy? |
| Q34211617 | Carboxypeptidase U at the interface between coagulation and fibrinolysis |
| Q37781402 | Coagulation factor XI as a novel target for antithrombotic treatment. |
| Q33814642 | Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia |
| Q35575101 | Contact pathway of coagulation and inflammation |
| Q28543133 | Creating novel activated factor XI inhibitors through fragment based lead generation and structure aided drug design |
| Q24315027 | Crystal structures of the FXIa catalytic domain in complex with ecotin mutants reveal substrate-like interactions |
| Q79366427 | Deficiency in thrombin-activatable fibrinolysis inhibitor (TAFI) protected mice from ferric chloride-induced vena cava thrombosis |
| Q39117235 | Differential Roles for the Coagulation Factors XI and XII in Regulating the Physical Biology of Fibrin. |
| Q50096411 | Discovery of thrombin activatable fibrinolysis inhibitor (TAFI). |
| Q30843513 | Enhanced endogenous thrombolysis induced by a specific factor Xa inhibitor, DX-9065a, evaluated in a rat arterial thrombolysis model in vivo. |
| Q27024190 | Factor XI and contact activation as targets for antithrombotic therapy |
| Q37033749 | Factor XI as a Therapeutic Target. |
| Q26865096 | Future prospects for contact factors as therapeutic targets |
| Q46688667 | In vitro, antithrombotic and bleeding time studies of BMS-654457, a small-molecule, reversible and direct inhibitor of factor XIa. |
| Q39739972 | In vivo regulation of plasminogen function by plasma carboxypeptidase B. |
| Q40167914 | Inhibition of Factor XII-Mediated Activation of Factor XI Provides Protection Against Experimental Acute Ischemic Stroke in Mice. |
| Q38117742 | Insights into thrombin activatable fibrinolysis inhibitor function and regulation. |
| Q53782006 | Is resistance futile? The role of activated thrombin-activatable fibrinolysis inhibitor resistance in bleeding in factor XI deficiency. |
| Q37207774 | Low thrombin activatable fibrinolysis inhibitor activity levels are associated with an increased risk of a first myocardial infarction in men |
| Q36562568 | P1 and P2' site mutations convert protease nexin-2 from a factor XIa inhibitor to a plasmin inhibitor |
| Q37071138 | Prevention of vascular graft occlusion and thrombus-associated thrombin generation by inhibition of factor XI |
| Q73472411 | Proteolytic activation of purified human procarboxypeptidase U |
| Q44365963 | Stabilization versus inhibition of TAFIa by competitive inhibitors in vitro |
| Q37124827 | Survival advantage of coagulation factor XI-deficient mice during peritoneal sepsis |
| Q28508572 | Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis |
| Q41863794 | The effects of intrinsic pathway protease deficiencies on plasminogen-deficient mice |
| Q36106323 | The kunitz protease inhibitor domain of protease nexin-2 inhibits factor XIa and murine carotid artery and middle cerebral artery thrombosis |
| Q37853060 | The many faces of the contact pathway and their role in thrombosis |
| Q36124038 | The neurovascular unit and combination treatment strategies for stroke |
| Q36606627 | Thrombin activatable fibrinolysis inhibitor (TAFI)--how does thrombin regulate fibrinolysis? |
| Q34786346 | Thrombin-activatable fibrinolysis inhibitor (TAFI) deficiency is compatible with murine life |
| Q34215746 | Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypeptidase U). |
| Q36384872 | Thrombin-thrombomodulin connects coagulation and fibrinolysis: more than an in vitro phenomenon |
Search more.